Skip to main content

Table 1 Characteristics of total patients with metastatic bone disease

From: Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

Factors

BP group

N = 262

Non-BP group

N = 55

P-value||

Age, median years (range)

45.5 (25–77)

50 (30–68)

NS*

PS** (ECOG ≥ 2)

10/166 (6.0%)

2/27 (7.4%)

NS

Pre-menopausal

79/176 (44.9%)

7/30 (23.3%)

0.027

Post-menopausal

97/176 (55.1%)

23/30 (76.7%)

 

ER***/PR positive

202 (77.1%)

28 (50.9%)

< 0.001

HER2 positive

72 (27.5%)

23 (41.8%)

0.035

DFI (month, median, range)

25 (0–230)

21 (0–174)

NS

Initial stage IV

61 (23.4%)

11 (20%)

NS

Adjuvant treatment

   

   Radiotherapy

111 (42.4%)

27 (49.1%)

NS

   Chemotherapy

176 (67.2%)

38 (69.1%)

NS

   Hormonal therapy

127 (48.5%)

21 (38.2%)

NS

Metastatic sites

   

   Visceral (liver, lung)

116 (44.3%)

37 (67.3%)

0.002

   LNs§

119 (45.4%)

30 (54.5%)

NS

   Soft tissue

78 (29.8%)

20 36.4%)

NS

   Bone only

81 (30.9%)

8 (14.5%)

0.014

   Weight bearing bone involvement

225 (86.2%)

25 (45.5%)

< 0.001

   Sum of metastatic sites (range)

2 (1–6)

3 (1–6)

0.006

Cycles of palliative chemotherapy

  

NS

   1

36 (13.7%)

8 (14.5%)

 

   2

53 (20.2%)

13 (23.6%)

 

   ≥ 3

157 (59.9%)

29 (52.7%)

 

Palliative AI use

168 (64.1%)

23 (41.8%)

0.002

Palliative anti-HER2 therapy

58/72 (80.6%)

20/23 (86.9%)

NS

Disease progression in bone (n)

97 (47.8%)

21 (38.2%)

NS

SREs (except the first event)

63 (27.2%)

21 (24.7%)

NS

  1. Abbreviations:*, not significant; **, performance status; ***, estrogen receptor; †, progesteron receptor;
  2. ‡, disease free interval; § lymph nodes; ¶ aromatase inhibitor; ||, P-value was obtained by chi-square test except variables of age and DFI which were obtained through Mann-Whitney U test